Open Research Studies at the Penn Memory Center

AVID image

The purpose of the AVID study is to evaluate the safety and imaging characteristics of an investigational PET imaging agent that binds to a protein called tau. Being able to measure tau protein is of considerable importance for tracking brain changes associated with Alzheimer’s disease.

This new PET tracer has potential application as a marker for assessing disease severity and may be useful in selecting patients for therapy and for monitoring disease progression.

Individuals at least 50 years of age with Mild Cognitive Impairment, Alzheimer’s disease or normal cognition may be eligible for this study.

Download a one-page overview of this study including contact information (for Individuals with Mild Cognitive Impairment or Alzheimer’s disease).

Download a one-page overview of this study including contact information (for Individuals normal cognition).

 

Merck BACE 1 MCI Handoutimage

The Merck BACE-1 Study is a Phase III study for patients with Mild Cognitive Impairment testing the safety, tolerability and cognitive effects of the Merck BACE inhibitor drug. This study is for individuals 50-85 years of age with a diagnosis of mild cognitive impairment.

This drug is not FDA approved and is investigational. As a BACE inhibitor, the drug inhibits the enzyme that produces beta amyloid plaques, deposits of which accumulate in the brains of patients with Alzheimer’s disease. The study will assess the effects of the drug on cognition and the ability to perform everyday activities.

Participants must have a reliable study partner: a spouse, relative, or friend who knows the participant well and sees him or her often, who will attend all study visits, and who will provide information about the participant during the study.

Download a one-page overview of this study including contact information

A4 Handout image

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 for short), is a clinical research study for older individuals who may be at risk for Alzheimer’s disease (AD). The A4 study is investigating a drug intervention, solanezumab, and Individuals 65-85 years of age with normal cognition may be eligible. The study requires infusion visits every four weeks, for a total of 42 infusion visits over three consecutive years.

 

Download a one-page overview of this study including contact information

Welcome to Penn Memory Center

The Penn Memory Center is now registering for Fall 2014 Cognitive Fitness Classes!

Register by August 15, 2014 for a 15% discount

Cognitive Fitness is an 8-week comprehensive, holistic program designed to educate and empower participants to age in the healthiest way possible. The course focuses on memory and thinking, organization, and the promotion of physical and emotional well-being. Strengthen your “memory muscle” and receive individual coaching on lifestyle changes that are important for optimal brain aging. Classes will run between September 29th – November 21st, 2014, at two convenient locations. Groups of no more than ten participants will meet two days per week for three hours per day. Both morning and afternoon classes are currently being offered at each location:

West Philadelphia
Perelman Center for Advanced Medicine
Monday and Wednesdays
AM Group  9:30AM – 12:30PM
- or -
PM Group  1:30PM – 4:30PM

Valley Forge
Penn Medicine Valley Forge
Tuesdays and Thursdays
AM Group  9:30AM – 12:30PM
- or -
PM Group  1:30PM – 4:30PM

Cost and Scholarships:

The full tuition for the Cognitive Fitness program is $1,800 per person. However, need-based scholarships are available upon request. Click here for Sliding Scale Fee for more information and application instructions.

Cognitive Screening:

Prior to enrollment, a clinical interview and cognitive pre-screening will be completed to help identify area of strength and weakness, while establishing individual goals and objectives for the course. To set up an appointment, please contact me by phone or email. The cost of the pre-screening is generally covered by private insurance or Medicare.

Registration:

To register, or more info, call 215-662-6734 or email at Scott.Reid@uphs.upenn.edu. The deadline for registration is September 1st, 2014. Register prior to August 15th and receive 15% off (full tuition participants only).

To download a flier, click here.

_______________________________________________________________________________________

 

The A4 Study is Now Enrolling at the Penn Memory Center

If you are a healthy older adult with normal memory, now is the time to join the fight to prevent Alzheimer’s disease.

The A4 study is a historic clinical trial for older individuals who may be at risk for Alzheimer’s disease (AD). The study aims to prevent the memory loss associated with Alzheimer’s disease (AD).

You can read more about the study and the eligibility requirements at the A4 Study website.

_______________________________________________________________________________________

Do you have a passion, talent, or skill that you would like to share with others?

Research tells us that cognitive stimulation and social engagement are key components to successful aging. The Penn Memory Center is pleased to provide a platform for our patients and community to come together and learn from one another. If you would like to volunteer to lead a book club or a discussion group, teach knitting, lead a yoga class, or share another skill with others at the Penn Memory Center, we are happy to host, promote and provide some administrative assistance to transform your interest into action.

Interested volunteers should contact Felicia Greenfield at 215-614-1828 or felicia.greenfield@uphs.upenn.edu.



News and Events

Alzheimer’s disease experts are testing an unusual approach to the disease: giving the brain what may be a more efficient
Read More


USA Today, citing a Finnish study presented on Sunday, July 13, 2014 at the Alzheimer’s Association International Conference in Denmark,
Read More


An article in the June 2014 issue of Managed Care examines the U.S. Preventive Services Task Force’s recent recommendation declaring
Read More


American seniors have lost an estimated $2.9 billion in financial scams in the last decade, and financial institutions need to
Read More


Myrna Roach and Donald Jackson are the Penn Memory Center’s first two participants in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s
Read More